Zoetis Inc. $ZTS Shares Sold by Westwood Holdings Group Inc.

Westwood Holdings Group Inc. reduced its stake in shares of Zoetis Inc. (NYSE:ZTS) by 3.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 130,852 shares of the company’s stock after selling 4,012 shares during the quarter. Westwood Holdings Group Inc.’s holdings in Zoetis were worth $20,406,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the company. Lindbrook Capital LLC raised its holdings in Zoetis by 1.8% during the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company’s stock worth $612,000 after purchasing an additional 65 shares during the last quarter. Scott & Selber Inc. raised its position in Zoetis by 0.6% during the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock worth $1,817,000 after acquiring an additional 67 shares during the last quarter. Secure Asset Management LLC grew its position in shares of Zoetis by 2.9% in the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock valued at $382,000 after purchasing an additional 68 shares during the last quarter. Moment Partners LLC raised its position in shares of Zoetis by 3.2% during the 2nd quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock worth $367,000 after purchasing an additional 72 shares during the last quarter. Finally, CVA Family Office LLC grew its holdings in Zoetis by 6.7% during the 2nd quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock valued at $183,000 after buying an additional 74 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $120.78 on Friday. The firm has a market capitalization of $53.23 billion, a price-to-earnings ratio of 20.79, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The company has a 50 day moving average price of $140.92 and a 200 day moving average price of $151.47. Zoetis Inc. has a one year low of $117.26 and a one year high of $181.85. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is 33.67%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ZTS shares. Stifel Nicolaus set a $140.00 price target on Zoetis in a report on Tuesday, November 4th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. UBS Group reduced their target price on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. Morgan Stanley lowered their price target on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a report on Monday, November 10th. Finally, Argus reissued a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Six research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $180.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.